Chemotherapy-related Reactivation of Hepatitis B Infection: Updates in 2013

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2014 Oct 31

PMID 25356022

Citations 17

Authors

Hwi Young Kim

Won Kim

Affiliations

Soon will be listed here.

Abstract

Hepatitis B reactivation is a potentially serious complication of anticancer chemotherapy, which occurs during and after therapy. This condition affects primarily hepatitis B surface antigen (HBsAg)-positive patients, but sometimes HBsAg-negative patients can be at risk, based only on evidence of past infection or occult infection with a low titer of detectable hepatitis B virus (HBV) DNA. The clinical outcomes vary with the different degrees of virologic and biochemical rebound, ranging from asymptomatic elevations in liver enzymes to hepatic failure and even death. Despite the remarkable advancement in the treatment of chronic hepatitis B over the past decade, proper strategies for the prevention and management of HBV reactivation remain elusive. Moreover, with the increasing use of rituximab in patients with lymphoma, HBV reactivation in occult or past infections has become increasingly problematic, especially in HBV-endemic regions. This review addresses the current knowledge on the clinical aspects and management of chemotherapy-related HBV reactivation, updates from recent reports, several unresolved issues and future perspectives.

Citing Articles

Viral Hepatitis B Reactivation With Delayed Cholestatic Effect Secondary to Acalabrutinib.

Shaikh A, Abraham S, Wang L, Torres H, Zhang H ACG Case Rep J. 2024; 11(6):e01387.

PMID: 38903451 PMC: 11188864. DOI: 10.14309/crj.0000000000001387.

Predictive value of hepatitis B serological indicators for mortality among cancer survivors and validation in a gastric cancer cohort.

Zhang Y, Qu L, Pan Y, Wu Y, Jiang J PLoS One. 2023; 18(12):e0286441.

PMID: 38150459 PMC: 10752528. DOI: 10.1371/journal.pone.0286441.

Hepatitis B Surface Antibody (Anti-HBs) Kinetics during Rituximab Chemotherapy and Performance of Hepatitis B Vaccine before Immunosuppression: Two Prospective Studies.

de Araujo-Neto J, Guimaraes G, Fernandes F, Soares M Viruses. 2022; 14(8).

PMID: 36016402 PMC: 9415137. DOI: 10.3390/v14081780.

COVID-19 Pandemic Impact on Cord Blood Collection for Stem Cell Use and Actual Perspectives.

Daia M, Median D, Buinoiu N, Ciocarlan M, Iancu G, Panaitescu A Maedica (Bucur). 2021; 16(2):184-188.

PMID: 34621337 PMC: 8450644. DOI: 10.26574/maedica.2021.16.2.189.

HBV Reactivation During the Treatment of Non-Hodgkin Lymphoma and Management Strategies.

Cao X, Wang Y, Li P, Huang W, Lu X, Lu H Front Oncol. 2021; 11:685706.

PMID: 34277431 PMC: 8281013. DOI: 10.3389/fonc.2021.685706.

References

Dienstag J . Hepatitis B virus infection. N Engl J Med. 2008; 359(14):1486-500. DOI: 10.1056/NEJMra0801644. View

Nagamatsu H, Kumashiro R, Itano S, Matsugaki S, Sata M . Investigation of associating factors in exacerbation of liver damage after chemotherapy in patients with HBV-related HCC. Hepatol Res. 2003; 26(4):293-301. DOI: 10.1016/s1386-6346(03)00158-x. View

Matsui T, Kang J, Nojima M, Tomonari A, Aoki H, Yamazaki H . Reactivation of hepatitis B virus in patients with undetectable HBsAg undergoing chemotherapy for malignant lymphoma or multiple myeloma. J Med Virol. 2013; 85(11):1900-6. DOI: 10.1002/jmv.23694. View

Mya D, Han S, Linn Y, Hwang W, Goh Y, Tan D . Risk of hepatitis B reactivation and the role of novel agents and stem-cell transplantation in multiple myeloma patients with hepatitis B virus (HBV) infection. Ann Oncol. 2011; 23(2):421-6. DOI: 10.1093/annonc/mdr142. View

Hsu C, Tsou H, Lin S, Wang M, Yao M, Hwang W . Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology. 2013; 59(6):2092-100. DOI: 10.1002/hep.26718. View

Matsue K, Kimura S, Takanashi Y, Iwama K, Fujiwara H, Yamakura M . Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma. Cancer. 2010; 116(20):4769-76. DOI: 10.1002/cncr.25253. View

Long M, Jia W, Li S, Jin L, Wu J, Rao N . A single-center, prospective and randomized controlled study: Can the prophylactic use of lamivudine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy?. Breast Cancer Res Treat. 2011; 127(3):705-12. DOI: 10.1007/s10549-011-1455-9. View

Takai S, Tsurumi H, Ando K, Kasahara S, Sawada M, Yamada T . Prevalence of hepatitis B and C virus infection in haematological malignancies and liver injury following chemotherapy. Eur J Haematol. 2005; 74(2):158-65. DOI: 10.1111/j.1600-0609.2004.00376.x. View

Zurawska U, Hicks L, Woo G, Bell C, Krahn M, Chan K . Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis. J Clin Oncol. 2012; 30(26):3167-73. DOI: 10.1200/JCO.2011.40.7510. View

10.

Ling W, Soe P, Pang A, Lee S . Hepatitis B virus reactivation risk varies with different chemotherapy regimens commonly used in solid tumours. Br J Cancer. 2013; 108(10):1931-5. PMC: 3670504. DOI: 10.1038/bjc.2013.225. View

11.

Tanaka Y, Esumi M, Shikata T . Persistence of hepatitis B virus DNA after serological clearance of hepatitis B virus. Liver. 1990; 10(1):6-10. DOI: 10.1111/j.1600-0676.1990.tb00429.x. View

12.

Yeo W, Johnson P . Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology. 2006; 43(2):209-20. DOI: 10.1002/hep.21051. View

13.

Yeo W, Chan T, Leung N, Lam W, Mo F, Chu M . Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol. 2008; 27(4):605-11. DOI: 10.1200/JCO.2008.18.0182. View

14.

Gupta S, Govindarajan S, Fong T, Redeker A . Spontaneous reactivation in chronic hepatitis B: patterns and natural history. J Clin Gastroenterol. 1990; 12(5):562-8. DOI: 10.1097/00004836-199010000-00015. View

15.

Engels E, Cho E, Jee S . Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study. Lancet Oncol. 2010; 11(9):827-34. PMC: 2933963. DOI: 10.1016/S1470-2045(10)70167-4. View

16.

Saab S, Dong M, Joseph T, Tong M . Hepatitis B prophylaxis in patients undergoing chemotherapy for lymphoma: a decision analysis model. Hepatology. 2007; 46(4):1049-56. DOI: 10.1002/hep.21783. View

17.

Yeo W, Chan P, Ho W, Zee B, Lam K, Lei K . Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol. 2004; 22(5):927-34. DOI: 10.1200/JCO.2004.05.161. View

18.

Ji D, Cao J, Hong X, Li J, Wang J, Chen F . Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study. Eur J Haematol. 2010; 85(3):243-50. DOI: 10.1111/j.1600-0609.2010.01474.x. View

19.

Marino D, Boso C, Crivellari G, Mazzarotto R, Stragliotto S, Farinati F . Fatal HBV-related liver failure during lamivudine therapy in a patient with non-Hodgkin's lymphoma. Tumori. 2008; 94(5):748-9. DOI: 10.1177/030089160809400519. View

20.

Lok A, McMahon B . Chronic hepatitis B: update 2009. Hepatology. 2009; 50(3):661-2. DOI: 10.1002/hep.23190. View